GJE client Cardior Pharmaceuticals raises €15 million

On May 11th 2017, Cardior Pharmaceuticals announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Meyers-Squibb (BMS), BioMedPartners and High-Tech Gründerfonds (HTGF). Cardior is pioneering its proprietary RNA technology to revolutionise predicting and treating heart failure. The molecular targets are non-coding RNAs linked to heart failure development that simultaneously control cardiac growth and calcium handling/contractility of cardiomyocytes. The targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodelling and restores normal cardiac function.

Gill Jennings and Every LLP advised the investor Syndicate led by LSP on the IP-related aspects of the transaction, including due diligence and freedom to operate analysis. The GJE team was led by partner John Jappy, assisted by Alice Baker.

Read the full press release here.

GJE has a dedicated investor group, focused on understanding the needs of today’s investors and developing services to meet those needs. See here for more information.